JNJ-Super company, Super stock! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : JNJ-Super company, Super stock!

JNJ 159.46

-0.5%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	3/11/2010 9:14:03 AM
	Read Replies (1) of 552

Jack Lief of Arena Pharm. said in early January that Ortho McNeil was moving a novel molecule forward in clinical testing for type II diabetes. It would only be a phase II study, but it's directed against a novel target (GPR119) and a huge market. While not a material disclosure for JNJ, it certainly is one for Arena. Does anybody here know of any FORMAL notice that Ortho has moved this molecule forward in testing? Thanks for any help! If you're interested, here are links. But they'll require registration to get to them, I believe..... the key part is at 16:25...... metameetings.com metameetings.com (links probably won't work without registration and login) "so, so, let me just mention that Ortho McNeil Johnson and Johnson is moving our type 2 diabetes compound APD597 forward and we've received over $50 million from JNJ we hope to have double digit royalties as well as significant milestones in the future."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next